Next |
home / stock / rtrx / rtrx message board
Subject | By | Source | When |
---|---|---|---|
Got snuffed for half when it dipped to | KOmani | investorshub | 08/22/2019 7:43:00 PM |
Glad I never jumped in. | Glider549 | investorshub | 08/22/2019 3:40:38 PM |
As of last public report, more than 4 | KOmani | investorshub | 08/22/2019 2:26:34 PM |
Seems like a good chunk of the selling | KOmani | investorshub | 08/22/2019 2:20:59 PM |
Seems markets didnt like phase 3 results | stock1ace1 | investorshub | 08/22/2019 11:57:52 AM |
Any day now, Phase 3 data. | Glider549 | investorshub | 07/16/2019 10:05:25 AM |
since 2016 -- when the symbol was changed | ernie44 | investorshub | 10/31/2018 1:03:41 AM |
Chart Analysis https://www.youtube.com/watch?v=IqornE5bTV8 | Shortmetina | investorshub | 09/08/2016 12:09:20 AM |
$RTRX bullish 18.48 | stocktrademan | investorshub | 07/16/2016 4:22:58 PM |
$RTRX bullish 18.46 | stocktrademan | investorshub | 07/01/2016 8:54:24 PM |
Harry has posted Charts of the Day video | thetechtrader | investorshub | 06/23/2016 12:37:11 PM |
Clearing Up The Shkreli Confusion - article mentions $RTRX | trendmkr | investorshub | 12/18/2015 3:51:55 PM |
I don't know. I'm not up to speed | UpTickMeA$AP | investorshub | 12/17/2015 8:20:52 PM |
,,,,,,,WHY IS $KBIO HALTED AND$ RTRX IS NOT??? | MONEYMADE | investorshub | 12/17/2015 8:14:27 PM |
Bye Shrek. You done f'ed up. | UpTickMeA$AP | investorshub | 12/17/2015 2:21:05 PM |
Looking like the Champ:Go$$$$ | dennisb | investorshub | 08/06/2015 3:56:42 AM |
Broke 30s tighten your seatbelt to take off$$$$$$$: | dennisb | investorshub | 05/29/2015 2:40:06 AM |
I've been bullish since January 14: where have | dennisb | investorshub | 05/26/2015 12:34:28 AM |
$RTRX recent news/filings | stocktrademan | investorshub | 05/18/2015 9:06:29 PM |
Price target raised $48: | dennisb | investorshub | 04/26/2015 6:11:53 PM |
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced completion of patient enrollment in the Phase 3 DUPLEX Study. The pivotal DUPLEX Study is evaluating the safety and efficacy of sparsentan for the treatment of focal segmental glomerulosclerosis...
New name reflects dedication to patient- inspired mission of identifying, developing and delivering life-changing rare disease therapies Company’s s hares to t rade u nder n ew t icker s ymbol TVTX on Novem...
SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced the completion of its previously announced acquisition of Orphan Technologies Limited, a privately held, clinical-stage biopharmaceutical company focused on the development of product candidate OT-58...